<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509415</url>
  </required_header>
  <id_info>
    <org_study_id>HS-MAV-003</org_study_id>
    <nct_id>NCT03509415</nct_id>
  </id_info>
  <brief_title>Reflectance Confocal Microscopy to Diagnose BCC</brief_title>
  <official_title>Reflectance Confocal Microscopy to Diagnose Basal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skin Care Network Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Skin Care Network Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is proposed to undertake a study to determine the diagnostic utility of using RCM for the&#xD;
      diagnosis of Basal Cell Carcinoma (BCC) in a tertiary referral centre as outlined by the&#xD;
      recent NICE report (Nov 2015). This will allow an assessment of the potential to avoid&#xD;
      diagnostic biopsy within the treatment pathway.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design This is an observational, non-randomised, non-controlled, prospective cohort&#xD;
      study to look at the efficacy of in vivo RCM as a diagnostic tool in the diagnosis of BCC.&#xD;
&#xD;
      Study Hypothesis The hypothesis of this study is that the use of RCM is would enable a&#xD;
      reduction in the number of diagnostic biopsies taken before definitive treatment of BCC by at&#xD;
      least 50%.&#xD;
&#xD;
      The secondary hypothesis is that the intra- &amp; inter-observer agreement for interpreting the&#xD;
      RCM images will have kappa scores 0.6 or greater (indicating good agreement).&#xD;
&#xD;
      Patients will be recruited from the outpatient clinic of Skin Care Network London.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity</measure>
    <time_frame>During exam (biopsy results typically available within one week).</time_frame>
    <description>Specificity &amp; Sensitivity of RCM in diagnosing Basal Cell Carcinoma in non-pigmented lesions compared to standard histology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intra- &amp; inter-observer agreement for interpreting the RCM images</measure>
    <time_frame>6 months</time_frame>
    <description>A measure of how consistently readers can diagnose from confocal images.</description>
  </secondary_outcome>
  <enrollment type="Actual">324</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>In-vivo imaging</intervention_name>
    <description>Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting at a skin cancer clinic with a lesion that is clinically suspicious for&#xD;
        BCC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older&#xD;
&#xD;
          2. Patient suspected of having a primary basal cell carcinoma that is a candidate for&#xD;
             surgical treatment.&#xD;
&#xD;
          3. Patient willing and able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recurrent or other higher-risk BCC&#xD;
&#xD;
          2. Patient with basal cell naevus syndrome&#xD;
&#xD;
          3. Patient treated with hedgehog inhibitor medication (vismodegib)&#xD;
&#xD;
          4. Patient not suitable for diagnostic biopsy&#xD;
&#xD;
          5. Location of lesion unsuitable, inaccessible or impractical for scanning with RCM as&#xD;
             determined by investigator&#xD;
&#xD;
          6. Patient with co-morbidities such as other skin disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Howard Stevens, MA PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Care Network Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Care Network Barnet Ltd</name>
      <address>
        <city>London</city>
        <zip>EN5 4QS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Confocal</keyword>
  <keyword>RCM</keyword>
  <keyword>Imaging</keyword>
  <keyword>Skin cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03509415/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

